
NanoViricides Partners with Regulatory Consultant to Pursue Orphan Drug Designation for NV-387 Antiviral
NanoViricides has engaged regulatory consultant Only Orphans Cote to develop an orphan drug strategy for its broad-spectrum antiviral NV-387, potentially securing significant regulatory benefits for treatments targeting smallpox, MPox, and measles.
Read full story






















